在美国医疗中心对肺炎链球菌耐药亚群进行测试时头孢洛林的抗菌活性。
Antimicrobial activity of ceftaroline tested against drug-resistant subsets of Streptococcus pneumoniae from U.S. medical centers.
作者信息
Flamm Robert K, Sader Helio S, Farrell David J, Jones Ronald N
机构信息
JMI Laboratories, North Liberty, Iowa, USA.
出版信息
Antimicrob Agents Chemother. 2014;58(4):2468-71. doi: 10.1128/AAC.02557-13. Epub 2014 Feb 10.
Abstract
Streptococcus pneumoniae isolates (6,958) were collected from patients at 163 U.S. medical centers during 2009 through 2012. Isolates were evaluated for multidrug resistance (MDR) to penicillin, ceftriaxone, erythromycin, tetracycline, trimethoprim-sulfamethoxazole, and levofloxacin. Ceftaroline was 16-fold more potent than ceftriaxone (MIC50/MIC90, ≤0.25/2 μg/ml) against all isolates. For MDR isolates (35.2% of tested strains), ceftaroline (MIC50/MIC90, 0.06/0.25 μg/ml; 100.0% susceptible) was the most active agent tested, being 8-fold more potent than ceftriaxone (MIC50/MIC90, 0.5/2 μg/ml) and 16-fold more potent than penicillin (MIC50/MIC90, 1/4 μg/ml).
摘要
2009年至2012年期间，从美国163家医疗中心的患者中收集了6958株肺炎链球菌分离株。对分离株进行了对青霉素、头孢曲松、红霉素、四环素、甲氧苄啶-磺胺甲恶唑和左氧氟沙星的多重耐药性（MDR）评估。头孢洛林对所有分离株的效力比头孢曲松高16倍（MIC50/MIC90，≤0.25/2μg/ml）。对于多重耐药分离株（占测试菌株的35.2%），头孢洛林（MIC50/MIC90，0.06/0.25μg/ml；100.0%敏感）是测试的最具活性的药物，其效力比头孢曲松（MIC50/MIC90，0.5/2μg/ml）高8倍，比青霉素（MIC50/MIC90，1/4μg/ml）高16倍。
相似文献
1
Antimicrobial activity of ceftaroline tested against drug-resistant subsets of Streptococcus pneumoniae from U.S. medical centers.在美国医疗中心对肺炎链球菌耐药亚群进行测试时头孢洛林的抗菌活性。
Antimicrob Agents Chemother. 2014;58(4):2468-71. doi: 10.1128/AAC.02557-13. Epub 2014 Feb 10.
2
Ceftaroline Activity Against Multidrug-Resistant Streptococcus pneumoniae from U.S. Medical Centers (2014) and Molecular Characterization of a Single Ceftaroline Nonsusceptible Isolate.头孢洛林对来自美国医疗中心的耐多药肺炎链球菌的活性（2014年）以及一株对头孢洛林不敏感菌株的分子特征分析
Microb Drug Resist. 2017 Jul;23(5):571-579. doi: 10.1089/mdr.2016.0258. Epub 2016 Dec 5.
3
Antimicrobial activity of ceftaroline and comparator agents tested against organisms isolated from patients with community-acquired bacterial pneumonia in Europe, Asia, and Latin America.检测分离自欧洲、亚洲和拉丁美洲社区获得性细菌性肺炎患者的病原体，评估头孢洛林与对照药物的抗菌活性。
Int J Infect Dis. 2018 Dec;77:82-86. doi: 10.1016/j.ijid.2018.10.004. Epub 2018 Oct 10.
4
Dalbavancin Activity When Tested against Streptococcus pneumoniae Isolated in Medical Centers on Six Continents (2011 to 2014).达巴万星对六大洲医疗中心分离出的肺炎链球菌进行检测时的活性（2011年至2014年）
Antimicrob Agents Chemother. 2016 May 23;60(6):3419-25. doi: 10.1128/AAC.00116-16. Print 2016 Jun.
5
Antimicrobial resistance profile and multidrug resistance patterns of Streptococcus pneumoniae isolates from patients suspected of pneumococcal infections in Ethiopia.埃塞俄比亚疑似肺炎链球菌感染患者分离株的抗菌药物耐药谱及多药耐药模式。
Ann Clin Microbiol Antimicrob. 2021 Apr 20;20(1):26. doi: 10.1186/s12941-021-00432-z.
6
Antimicrobial activity of ceftaroline and comparator agents tested against bacterial isolates causing skin and soft tissue infections and community-acquired respiratory tract infections isolated from the Asia-Pacific region and South Africa (2010).检测亚太地区和南非分离的致皮肤软组织感染和社区获得性呼吸道感染的细菌分离株的抗菌活性：头孢洛林和比较剂（2010 年）。
Diagn Microbiol Infect Dis. 2013 May;76(1):61-8. doi: 10.1016/j.diagmicrobio.2013.01.005. Epub 2013 Mar 25.
7
In vitro activity of new cephalosporins vs Streptococcus pneumoniae from the Canadian Bacterial Surveillance Network: 2008-2011.加拿大细菌监测网络中新型头孢菌素对肺炎链球菌的体外活性：2008 - 2011年
Curr Microbiol. 2014 Nov;69(5):763-7. doi: 10.1007/s00284-014-0622-8. Epub 2014 Jul 15.
8
Ceftaroline activity against organisms isolated from respiratory tract infections in USA hospitals: results from the AWARE Program, 2009-2011.头孢洛林对美国医院呼吸道感染分离菌的活性：2009-2011 年 AWARE 项目的结果。
Diagn Microbiol Infect Dis. 2014 Apr;78(4):437-42. doi: 10.1016/j.diagmicrobio.2013.10.020. Epub 2013 Nov 6.
9
Ceftaroline activity against bacterial pathogens frequently isolated in U.S. medical centers: results from five years of the AWARE surveillance program.头孢洛林对美国医疗中心常见分离出的细菌病原体的活性：AWARE监测项目五年的结果。
Antimicrob Agents Chemother. 2015 Apr;59(4):2458-61. doi: 10.1128/AAC.04614-14. Epub 2015 Feb 2.
10
Antimicrobial Activity of Ceftaroline and Comparator Agents Against Ceftriaxone-Nonsusceptible from the United States (2008-2020).美国（2008-2020 年）耐头孢曲松的肺炎链球菌对抗菌药物的抗菌活性。
Microb Drug Resist. 2022 Sep;28(9):935-940. doi: 10.1089/mdr.2022.0046. Epub 2022 Aug 17.
引用本文的文献
1
Rationale and Logistics of Continuous Infusion Cephalosporin Antibiotics.头孢菌素类抗生素持续输注的原理与实施安排
Pharmacy (Basel). 2024 Dec 5;12(6):185. doi: 10.3390/pharmacy12060185.
2
Distribution of Multidrug-Resistant Invasive Serotypes of during the Period 2007-2021 in Madrid, Spain.2007年至2021年期间西班牙马德里多重耐药侵袭性血清型的分布情况
Antibiotics (Basel). 2023 Feb 7;12(2):342. doi: 10.3390/antibiotics12020342.
3
A Retrospective Analysis of Probability of Target Attainment in Community-Acquired Pneumonia: Ceftaroline Fosamil Versus Comparators.社区获得性肺炎目标达成概率的回顾性分析：头孢洛林酯与对照药物对比
Infect Dis Ther. 2019 Jun;8(2):185-198. doi: 10.1007/s40121-019-0243-4. Epub 2019 Apr 8.
4
Activities of Ceftaroline and Comparators against Streptococcus pneumoniae Isolates from U.S. Hospitals: Results from Seven Years of the AWARE Surveillance Program (2010 to 2016).美国医院分离的肺炎链球菌对头孢洛林及对照药物的活性：AWARE 监测项目（2010 至 2016 年）七年的结果。
Antimicrob Agents Chemother. 2018 Jan 25;62(2). doi: 10.1128/AAC.01555-17. Print 2018 Feb.
5
Use of Ceftaroline Fosamil in Children: Review of Current Knowledge and its Application.头孢洛林酯在儿童中的应用：当前知识综述及其应用
Infect Dis Ther. 2017 Mar;6(1):57-67. doi: 10.1007/s40121-016-0144-8. Epub 2016 Dec 30.
6
Dalbavancin Activity When Tested against Streptococcus pneumoniae Isolated in Medical Centers on Six Continents (2011 to 2014).达巴万星对六大洲医疗中心分离出的肺炎链球菌进行检测时的活性（2011年至2014年）
Antimicrob Agents Chemother. 2016 May 23;60(6):3419-25. doi: 10.1128/AAC.00116-16. Print 2016 Jun.
7
Ceftaroline activity against bacterial pathogens frequently isolated in U.S. medical centers: results from five years of the AWARE surveillance program.头孢洛林对美国医疗中心常见分离出的细菌病原体的活性：AWARE监测项目五年的结果。
Antimicrob Agents Chemother. 2015 Apr;59(4):2458-61. doi: 10.1128/AAC.04614-14. Epub 2015 Feb 2.
8
Examining the use of ceftaroline in the treatment of Streptococcus pneumoniae meningitis with reference to human cathelicidin LL-37.参照人源抗菌肽LL-37研究头孢洛林在治疗肺炎链球菌性脑膜炎中的应用。
Antimicrob Agents Chemother. 2015 Apr;59(4):2428-31. doi: 10.1128/AAC.04965-14. Epub 2015 Jan 20.
9
Emerging novel and antimicrobial-resistant respiratory tract infections: new drug development and therapeutic options.新出现的新型和耐药性呼吸道感染：新药研发与治疗选择
Lancet Infect Dis. 2014 Nov;14(11):1136-1149. doi: 10.1016/S1473-3099(14)70828-X. Epub 2014 Sep 1.
本文引用的文献
1
Spectrum and potency of ceftaroline tested against leading pathogens causing community-acquired respiratory tract infections in Europe (2010).针对欧洲引起社区获得性呼吸道感染的主要病原体，对头孢洛林的谱和效价进行了检测（2010 年）。
Diagn Microbiol Infect Dis. 2013 Jan;75(1):86-8. doi: 10.1016/j.diagmicrobio.2012.06.005. Epub 2012 Nov 10.
2
In vitro activity of ceftaroline against multidrug-resistant Staphylococcus aureus and Streptococcus pneumoniae: a review of published studies and the AWARE Surveillance Program (2008-2010).头孢洛林对耐多药金黄色葡萄球菌和肺炎链球菌的体外活性：对已发表研究和 AWARE 监测计划（2008-2010 年）的回顾。
Clin Infect Dis. 2012 Sep;55 Suppl 3:S206-14. doi: 10.1093/cid/cis563.
3
AWARE Ceftaroline Surveillance Program (2008-2010): trends in resistance patterns among Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States.AWARE 头孢洛林监测计划（2008-2010 年）：美国肺炎链球菌、流感嗜血杆菌和卡他莫拉菌耐药模式的趋势。
Clin Infect Dis. 2012 Sep;55 Suppl 3:S187-93. doi: 10.1093/cid/cis561.
4
Activity analyses of staphylococcal isolates from pediatric, adult, and elderly patients: AWARE Ceftaroline Surveillance Program.从儿科、成人和老年患者分离的葡萄球菌属的活性分析：AWARE 头孢洛林监测计划。
Clin Infect Dis. 2012 Sep;55 Suppl 3:S181-6. doi: 10.1093/cid/cis560.
5
Summary of ceftaroline activity against pathogens in the United States, 2010: report from the Assessing Worldwide Antimicrobial Resistance Evaluation (AWARE) surveillance program.美国 2010 年头孢洛林针对病原体的活性总结：来自评估全球抗菌药物耐药性监测（AWARE）计划的报告。
Antimicrob Agents Chemother. 2012 Jun;56(6):2933-40. doi: 10.1128/AAC.00330-12. Epub 2012 Apr 2.
6
Comparative ceftaroline activity tested against pathogens associated with community-acquired pneumonia: results from an international surveillance study.比较头孢洛林对与社区获得性肺炎相关病原体的活性：一项国际监测研究的结果。
J Antimicrob Chemother. 2011 Apr;66 Suppl 3:iii69-80. doi: 10.1093/jac/dkr101.
7
Ceftaroline fosamil: a new broad-spectrum cephalosporin.头孢呋辛酯：一种新型的广谱头孢菌素。
J Antimicrob Chemother. 2011 Apr;66 Suppl 3:iii11-8. doi: 10.1093/jac/dkr095.
8
In vitro activity of ceftaroline against gram-positive and gram-negative pathogens isolated from patients in Canadian hospitals in 2009.2009 年加拿大医院分离的革兰阳性和革兰阴性病原菌的体外 ceftaroline 活性。
Antimicrob Agents Chemother. 2011 Jun;55(6):2837-46. doi: 10.1128/AAC.01787-10. Epub 2011 Mar 14.
9
Ceftaroline fosamil: a novel broad-spectrum cephalosporin with expanded anti-Gram-positive activity.头孢呋辛酯：一种新型的广谱头孢菌素，具有扩展的抗革兰氏阳性活性。
J Antimicrob Chemother. 2010 Nov;65 Suppl 4:iv9-16. doi: 10.1093/jac/dkq251.
10
Declining antimicrobial susceptibility of Streptococcus pneumoniae in the United States: report from the SENTRY Antimicrobial Surveillance Program (1998-2009).美国肺炎链球菌对抗菌药物敏感性下降：哨兵抗菌药物监测项目（1998 - 2009年）报告
Diagn Microbiol Infect Dis. 2010 Nov;68(3):334-6. doi: 10.1016/j.diagmicrobio.2010.08.024.
Zotero 插件